APOQUEL DIN 02530651
Status: Marketed
Holder: ZOETIS CANADA INC
Health Canada record
| Active ingredient(s) | OCLACITINIB (OCLACITINIB MALEATE) 3.6 MG |
|---|
| Dosage form | Tablet (Chewable) |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 18-Jul-2023 |
|---|
| Current status date | 18-Jul-2023 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Zoetis Canada Inc — licence 102076, currently licensed, last inspection rating C (2023-10-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing OCLACITINIB (OCLACITINIB MALEATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02427885 | APOQUEL | ZOETIS CANADA INC | Tablet | OCLACITINIB (OCLACITINIB MALEATE) 3.6 MG | Marketed |
| 02427893 | APOQUEL | ZOETIS CANADA INC | Tablet | OCLACITINIB (OCLACITINIB MALEATE) 5.4 MG | Marketed |
| 02427907 | APOQUEL | ZOETIS CANADA INC | Tablet | OCLACITINIB (OCLACITINIB MALEATE) 16 MG | Marketed |
| 02530678 | APOQUEL | ZOETIS CANADA INC | Tablet (Chewable) | OCLACITINIB (OCLACITINIB MALEATE) 5.4 MG | Marketed |
| 02530686 | APOQUEL | ZOETIS CANADA INC | Tablet (Chewable) | OCLACITINIB (OCLACITINIB MALEATE) 16 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 32914 | 2024-03-20 | Supplement to a New Drug Submission (SNDS) | Addition of a drug substance supplier |
| 28948 | 2022-09-14 | Supplement to a New Drug Submission (SNDS) | New dosage form (chewable tablets) |
Request a quote for APOQUEL
How to read a Canadian DIN record